05 September 2019
Visiongain has launched a new pharma report Circulating Tumor Cells (CTC) Market Report 2019-2029: By Technology (CTC Detection Methods, CTC Enrichment Methods), by Application (Epithelial-Mesenchymal Transition (EMT) Biomarkers Development, Cancer Cell Research Segment, Others), by End Users (Diagnostic Centers, Hospitals and Clinics Segment, Academic & Research Laboratories, Others).
Global CTC Market is anticipated to grow on account of growing chronic oncology disease cases and applications of CTC in biomarkers for drug discovery is anticipated to fuel the growth of global market. The global CTC market is anticipated to grow at a lucrative CAGR of 14.7% and anticipated to reach USD 26.82 Billion by 2029.
CTCs are a prevalent topic in cancer research since liquid biopsy can be used to monitor a patient's condition, which is a minimally invasive procedure with more sample accessibility in comparison to tissue biopsy. Over the past centuries, the CTC study covered a wide range of subjects, such as profiling, enumeration, and correlation between the amount of CTC and patient overall survival. It is vital to separate and enrich CTCs before performing a CTC assessment because CTCs are very prevalent in blood flow (0–10 CTCs/mL of blood sample). Among various solutions to divide CTCs, microfluidics provides numerous attractive advantages for CTC studies, such as continuing sample processing to reduce target cell loss and easy integration of multiple characteristics into a chip, enabling "do-everything-on - a-chip."
The significance of early diagnosis of cancer and better cancer therapy has been obvious for years, and worldwide study has been introduced into fresh possibilities in the care strategy of cancer patients using technological innovations. One of the primary fields of study involves the detection and separation of CTC owing to their vital role in early diagnosis and prognosis of cancer.
Currently, cancer-related diseases are one of the major health issues in the world, causing around eight million deaths each year, and it is anticipated that this amount will increase rapidly in the future. Therefore, research on cancer therapy and early diagnostic techniques is essential. Modern, innovative methods can carry out tasks that were previously impossible. The primary diagnostic and therapy methods for cancer patients are gradually moving from standard norms to customized techniques due to these advances.
North America holds majority of market share followed by Europe and will continue to dominate in the future as a result of a number of research projects in the region, coupled with funding for research institutes from the government. In addition, the market will continue to be driven by the existence of target population and increased R&D investment by important business organizations. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to growing presence of cancer cases in markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost CTC market growth over the forecast period.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.
The comprehensive market report features companies such as AdnaGen AG, Advanced Cell Diagnostics, Apocell, Aviva Biosciences, Biocep Ltd., Biocept, Inc., Biofluidica, Canopus Biosciences, CellTraffix, Inc., CellTraffix, Inc., Clearbridge BioMedics, Creatv Microtech, Inc., Cynvenio Biosystems, Epic Biosciences, Fluxion Biosciences, Inc., GE Healthcare, Greiner Bio-one GmbH, F Hoffmann-La Roche Ltd, Ikonisys, Inc., Janssen Diagnostics, LungLife AI Inc., Menarini Silicon Biosystems, Menarini Silicon Biosystems, Miltenyi Biotech, Miltenyi Biotech, NanoString Technologies, Inc., Qiagen, SRI International, STEMCELL Technologies, Sysmex Corp., Thermo Fisher Scientific and Vitatex, Inc. among other prominent players.
Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.